It is a common perception that approximately 50% of heart failure (HF) patients present with a normal or near-normal left ventricular (LV) ejection fraction ("HF with preserved systolic function"), ...

Researchers identified distinct demographic, clinical, and serologic predictors of incident LVSD and cardiac recovery among patients with SSc.

An artificial intelligence (AI) algorithm trained to interpret single-lead ECGs from the Apple Watch accurately detected signs of subclinical left ventricular systolic dysfunction in a ...

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.

Cardiomyopathy is the leading cause of mortality in patients with DMD. Compared with their healthy counterparts, patients with DMD — including those with preserved left ventricular ejection fraction ...

Panel A shows a cross-section of a normal heart (top) and an endomyocardial biopsy sample from a normal heart (bottom; with hematoxylin and eosin staining) that shows normal histologic characteristics ...

Cytokinetics has announced that the US Food and Drug Administration (FDA) has approved MYQORZO (aficamten) tablets in 5mg, ...

FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA ...